AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLDI
  4. [S-3] Calidi Biotherapeutics, Inc. Shelf Registration Statement

[S-3] Calidi Biotherapeutics, Inc. Shelf Registration Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-3
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock CLDI logo
Calidi Biotherapeutics Inc

NYSE:CLDI

CLDI Rankings

#8715 Ranked by Market Cap
N/A Ranked by Dividends

CLDI Latest News

Jul 29, 2025
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
Jul 25, 2025
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on聽August 5, 2025
Jul 22, 2025
Join Calidi Biotherapeutics鈥� Exclusive Live Investor Webinar and Q&A Session on July 24
Jul 10, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
Jul 9, 2025
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

CLDI Latest SEC Filings

Jul 25, 2025
[8-K] Calidi Biotherapeutics, Inc. Reports Material Event
Jul 15, 2025
[Form 4] Calidi Biotherapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Calidi Biotherapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Calidi Biotherapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Calidi Biotherapeutics, Inc. Insider Trading Activity

CLDI Stock Data

20.20M
34.45M
5.43%
15.85%
0.84%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SAN DIEGO